These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16307566)

  • 1. Serum procalcitonin levels in patients with mild community-acquired pneumonia.
    Beović B; Kreft S; Osredkar J; Kese D; Bonac-Tuma B
    Clin Microbiol Infect; 2005 Dec; 11(12):1050-1. PubMed ID: 16307566
    [No Abstract]   [Full Text] [Related]  

  • 2. [Utility of serum procalcitonin as a diagnostic guide in children with community-acquired pneumonia].
    García-Zarza Martínez E; Ramos Amador JT; Rubio Gribble B; Corrales del Río E; Zeballos Sarrato G; Herrera Montes J
    An Pediatr (Barc); 2004 Mar; 60(3):279-81. PubMed ID: 14987523
    [No Abstract]   [Full Text] [Related]  

  • 3. Procalcitonin and severity of community-acquired pneumonia.
    Okimoto N; Hayashi Y; Ishiga M; Nanba F; Kishimoto M; Yagi S; Kurihara T; Asaoka N; Tamada S
    J Infect Chemother; 2009 Dec; 15(6):426-7. PubMed ID: 20012738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum procalcitonin level: clinical significance.
    Aggarwal D; Mohapatra PR; Aggarwal P
    Eur Respir J; 2011 Mar; 37(3):723; author reply 723. PubMed ID: 21357930
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarkers in community-acquired pneumonia.
    Krüger S; Welte T
    Expert Rev Respir Med; 2012 Apr; 6(2):203-14. PubMed ID: 22455492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric antimicrobial therapy of community-acquired pneumonia: clinical diagnosis versus procalcitonin levels.
    Cunha BA
    Scand J Infect Dis; 2009; 41(10):782-4. PubMed ID: 19681019
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.
    Don M; Valent F; Korppi M; Falleti E; De Candia A; Fasoli L; Tenore A; Canciani M
    Scand J Infect Dis; 2007; 39(2):129-37. PubMed ID: 17366029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A procalcitonin-guided algorithm for pneumonia may reduce antibiotic use and treatment duration].
    Berg P; Lindhardt BØ
    Ugeskr Laeger; 2012 Aug; 174(35):1986-9. PubMed ID: 22929575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia.
    Hirakata Y; Yanagihara K; Kurihara S; Izumikawa K; Seki M; Miyazaki Y; Kohno S
    Diagn Microbiol Infect Dis; 2008 Jun; 61(2):170-4. PubMed ID: 18329217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia--a clinical observation in geriatric patients.
    Heppner HJ; Bertsch T; Alber B; Esslinger AS; Dragonas C; Bauer JM; Sieber CC
    Gerontology; 2010; 56(4):385-9. PubMed ID: 19940454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleural Effusion Increases Serum Procalcitonin Values in Children with Community-acquired Pneumonia.
    Fonseca TS; Gendrel D; Ruuskanen O; Nascimento-Carvalho CM
    Pediatr Infect Dis J; 2015 Aug; 34(8):914-5. PubMed ID: 26020411
    [No Abstract]   [Full Text] [Related]  

  • 12. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
    Christ-Crain M; Stolz D; Bingisser R; Müller C; Miedinger D; Huber PR; Zimmerli W; Harbarth S; Tamm M; Müller B
    Am J Respir Crit Care Med; 2006 Jul; 174(1):84-93. PubMed ID: 16603606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.
    Jereb M; Kotar T
    Wien Klin Wochenschr; 2006 Apr; 118(5-6):170-4. PubMed ID: 16773483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin.
    Niederman MS
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S127-32. PubMed ID: 18986278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Community-acquired pneumonia and procalcitonin, an opportunity to improve?].
    Tudela P; Mòdol JM
    Med Clin (Barc); 2014 Apr; 142(7):303-5. PubMed ID: 24183120
    [No Abstract]   [Full Text] [Related]  

  • 16. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis.
    Polzin A; Pletz M; Erbes R; Raffenberg M; Mauch H; Wagner S; Arndt G; Lode H
    Eur Respir J; 2003 Jun; 21(6):939-43. PubMed ID: 12797485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of C-reactive protein and procalcitonin serum concentrations to guide differential diagnosis and clinical management of pneumococcal and Legionella pneumonia.
    Bellmann-Weiler R; Ausserwinkler M; Kurz K; Theurl I; Weiss G
    J Clin Microbiol; 2010 May; 48(5):1915-7. PubMed ID: 20220163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procalcitonin-based guidelines and lower respiratory tract infections.
    Stijnis C; van Nieuwkoop C; van Dissel JT
    JAMA; 2010 Feb; 303(5):418-9; author reply 419-20. PubMed ID: 20124533
    [No Abstract]   [Full Text] [Related]  

  • 19. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index.
    Masiá M; Gutiérrez F; Shum C; Padilla S; Navarro JC; Flores E; Hernández I
    Chest; 2005 Oct; 128(4):2223-9. PubMed ID: 16236878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum procalcitonin levels and empirical antibiotic treatment of patients with community-acquired febrile syndromes.
    Villanueva JL; Cervin RJ
    Clin Infect Dis; 2003 Mar; 36(6):822; author reply 826-7. PubMed ID: 12627370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.